ACCELERATED PROGRESSION RELAPSE TEST

摘要

An Accelerated Progression Relapse Test (APRT) and method is provided for use in the prognosis of a patient having an ER+ breast cancer. The APRT provides a determination of when a patient in a particular diseased state is likely to benefit from further disease treatment, or does not have a high probability of benefit with additional treatment. Four genetic probes are disclosed that target the MK167, CDC6 and SPAG5 gene and gene products. The ER+ breast cancer patient population is stratified into two groups, with the low gene expression group identifying the patient/patient group that is less likely to benefit from additional treatment measures, and a high gene expression group identifying the patient group that is more likely to benefit from additional treatment measures.

主权项

1. A method of selecting a treatment to administer to an ER+ breast cancer patient based on protein expression levels of a gene panel comprising:
comparing protein expression levels of a gene panel comprising the CDC6, MKI67, and SPAG5 gene in a primary breast tissue sample from the ER+ breast cancer patient to expression levels of the gene panel in a reference population of ER+ breast cancer patients; and administering an aggressive breast cancer treatment to the ER+ breast cancer patient when the patient primary breast tissue sample has a higher protein expression level than the reference population for at least one of the proteins of the gene panel, or not administering an aggressive breast cancer treatment to the ER+ breast cancer patient when the patient primary breast tissue sample has a lower protein expression level of each protein of the panel in the reference population.